Note: if you are unable to access this slide presentation it is because you need to register on the site (free); it may be of interest to those with clear cell ovarian cancer; the largest % of renal cancers are of the clear cell subtype (a known ~75%) ------------------------------------------------------------------------------------------------------- MODULE 1: Renal Cell Carcinoma Biology and Rationale for VEGF Expert review with Lee Lokey, MD, and Brian I. Rini, MD, focusing on renal cell carcinoma | |||
Discussant: | Brian I. Rini, MD—Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States | ||
Interviewed by: | Lee Lokey, MD—prIME Oncology, Atlanta, Georgia, United States |
Showing posts with label kidney cancer. Show all posts
Showing posts with label kidney cancer. Show all posts
Monday, March 28, 2011
Expert Review - slides: Renal Cell Carcinoma Biology and the Rationale for VEGF (sorafenib, sunitinib, erlotinib, avastin, interleukins, etc)
add your opinions
clear cell
,
erlotinib
,
kidney cancer
,
renal cell carcinoma
,
Sorafenib
,
sunitinib
Saturday, July 24, 2010
Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer (see 'Note')
Note: while not ovarian cancer specific (noting the common cell type of clear cell) the conclusion is interesting
CONCLUSION: We identified overweight as an independent prognostic marker of improved cancer specific survival in patients with organ-confined but not advanced RCC. Basic research is required to resolve the dilemma of why, if a higher BMI predisposes to RCC, it concurrently prolongs survival after patients have undergone (partial) nephrectomy.
add your opinions
clear cell
,
kidney cancer
,
obesity
,
overall survival
,
overweight
Subscribe to:
Posts
(
Atom
)